Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 6/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 6/20 | 0.62 |
| ▸ | CYP2D6 | P10635 | 6/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.62 |
| ▸ | TSHR | P16473 | 1/20 | 0.62 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.61 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.61 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.61 |
| ▸ | OPRL1 | P41146 | 3/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.61 |
| ▸ | KCNA5 | P22460 | 4/20 | 0.61 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.61 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | MC4R | P32245 | 3/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8916036 | 1.00 | CYP1A2 (0.62) | CYP1A2CYP2C19CYP2D6CYP3A4TSHR | |
| SCHEMBL8922757 | 0.98 | CYP1A2 (0.66) | CYP1A2CYP2C19CYP2D6CYP3A4TSHR | |
| SCHEMBL4334322 | 0.98 | CYP1A2 (0.66) | CYP1A2CYP2C19CYP2D6CYP3A4TSHR | |
| SCHEMBL30364119 | 0.96 | OPRM1 (0.61) | CYP1A2CYP2C19CYP2D6CYP3A4TSHR | |
| SCHEMBL30363975 | 0.96 | OPRM1 (0.61) | CYP1A2CYP2C19CYP2D6CYP3A4TSHR | |
| SCHEMBL2962625 | 0.92 | OPRM1 (0.65) | CYP1A2CYP2C19CYP2D6CYP3A4TSHR | |
| SCHEMBL3246700 | 0.85 | SLC6A4 (0.63) | CYP1A2CYP2C19CYP2D6CYP3A4CYP2C9 | |
| SCHEMBL14593276 | 0.85 | MC4R (0.69) | CYP2C19CYP2D6TSHROPRM1OPRD1 | |
| SCHEMBL10598753 | 0.85 | OPRM1 (0.63) | CYP1A2CYP2C19CYP2D6CYP3A4TSHR | |
| SCHEMBL113896 | 0.83 | CYP1A2 (0.62) | CYP1A2CYP2C19CYP2D6CYP3A4TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0581456-A1 | Use of phenylpyrrolidines for the manufacture of a medicament for the treatment of neurodegenerative diseases | R.J. REYNOLDS TOBACCO COMPANY (US) | 1994-02-02 | — | — | EP | claimed |
| US-5248690-A | Nervous system disorders such as Parkinson*s disease | R. J. REYNOLDS TOBACCO COMPANY (US) | 1993-09-28 | — | — | US | claimed |
| US-11911371-B2 | Pyridine and pyrazine derivative for the treatment of chronic bronchitis | NOVARTIS AG (CH) | 2024-02-27 | — | — | US | disclosed |
| EP-3193604-B1 | SUBSTITUTED N-(PYRROLIDIN-3-YL)ISOXAZOLE-3-CARBOXAMIDE COMPOUNDS | EPIZYME INC (US) | 2021-06-16 | — | — | EP | disclosed |
| EP-3189046-B1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH INC (US) | 2020-08-26 | — | — | EP | disclosed |
| EP-2513028-B1 | METHOD FOR PREPARING ALIZARIN DERIVATIVE COMPOUND, NOVEL ALIZARIN DERIVATIVE COMPOUND, USE OF SAID ALIZARIN COMPOUND, PHOTOELECTRIC CONVERSION FILM, PHOTOELECTRIC CONVERSION ELEMENT, AND ELECTROPHOTOGRAPHIC PHOTORECEPTOR | FUJIFILM CORP (JP) | 2018-06-20 | — | — | EP | disclosed |
| WO-2017201468-A1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2017-11-23 | — | — | WO | disclosed |
| US-20170071919-A1 | Pyridine and Pyrazine derivative for the Treatment of CF | NOVARTIS AG (CH) | 2017-03-16 | — | — | US | disclosed |
| US-9365552-B2 | Pyridine and pyrazine derivative for the treatment of CF | NOVARTIS AG (CH) | 2016-06-14 | — | — | US | disclosed |
| EP-2547656-B1 | PYRIDINE AND PYRAZINE DERIVATIVE FOR THE TREATMENT OF CF | NOVARTIS AG (CH) | 2015-09-30 | — | — | EP | disclosed |
| EP-2845593-A1 | Pyridine and pyrazine derivative for the treatment of chronic obstructive pulmonary disease | Novartis AG (CH) | 2015-03-11 | — | — | EP | disclosed |
| WO-2011071130-A1 | METHOD FOR PREPARING ALIZARIN DERIVATIVE COMPOUND, NOVEL ALIZARIN DERIVATIVE COMPOUND, SURFACE MODIFICATION METHOD, PHOTOELECTRIC CONVERSION FILM, PHOTOELECTRIC CONVERSION ELEMENT, AND ELECTROPHOTOGRAPHIC PHOTORECEPTOR | FUJIFILM CORPORATION (JP) | 2011-06-16 | — | — | WO | disclosed |
| EP-1479397-B1 | 2,4,6-TRIAMINO-1,3,5-TRIAZINE DERIVATIVE | ASTELLAS PHARMA INC (JP) | 2011-06-08 | — | — | EP | disclosed |
| US-20080227785-A1 | 2,4,6-TRIAMINO-1,3,5-TRIAZINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2008-09-18 | — | — | US | disclosed |
| US-20080227785-A1 | 2,4,6-TRIAMINO-1,3,5-TRIAZINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2008-09-18 | — | — | US | disclosed |
| US-7375222-B2 | 2,4,6-Triamino-1,3,5-triazine derivative | ASTELLAS PHARMA INC. (JP) | 2008-05-20 | — | — | US | disclosed |
| US-7375222-B2 | 2,4,6-Triamino-1,3,5-triazine derivative | ASTELLAS PHARMA INC. (JP) | 2008-05-20 | — | — | US | disclosed |
| WO-2007006418-A1 | IONIC-LIQUID-CONTAINING PRODUCTS FOR DYEING AND/OR BRIGHTENING KERATIN FIBRES | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 2007-01-18 | — | — | WO | disclosed |
| EP-0581456-A1 | Use of phenylpyrrolidines for the manufacture of a medicament for the treatment of neurodegenerative diseases | R.J. REYNOLDS TOBACCO COMPANY (US) | 1994-02-02 | — | — | EP | disclosed |
| US-5248690-A | Nervous system disorders such as Parkinson*s disease | R. J. REYNOLDS TOBACCO COMPANY (US) | 1993-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11911371-B2 | Pyridine and pyrazine derivative for the treatment of chronic bronchitis | CFTR, OPRK1, CHRM3 | CYP1A2 328/4885CYP2C19 316/4885CYP2D6 812/4885 |
| US-20170071919-A1 | Pyridine and Pyrazine derivative for the Treatment of CF | CFTR, OPRK1, OPRD1 | CYP1A2 562/4885CYP2C19 456/4885CYP2D6 1014/4885 |
| US-20080227785-A1 | 2,4,6-TRIAMINO-1,3,5-TRIAZINE DERIVATIVE | KCNT1, KCNMA1, KCNJ2 | CYP1A2 3364/4885CYP2C19 4516/4885CYP2D6 4354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.